MSC-delivered High-Affinity Variants of soluble PD1 lead to tumour regression
Serap Gokcen, Tianyuan Chu, P Blair…·Andrea Mohr
This paper develops a cell-based immune checkpoint therapy using MSCs to deliver a high-affinity sPD1 variant, showing anti-tumour activity in a mouse model.